Recombinant PDCD1 (Nivolumab Biosimilar) antibody (AA 1-167)
Reactivity: Human
FACS, BR, IHC, SPR
Host: Rabbit
Chimeric
5C4-B8
unconjugated
Recombinant Antibody
-
- Target See all PDCD1 (Nivolumab Biosimilar) products
- PDCD1 (Nivolumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Binding Specificity
- AA 1-167
- Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Chimeric
-
Conjugate
- This PDCD1 (Nivolumab Biosimilar) antibody is un-conjugated
-
Application
- Flow Cytometry (FACS), Blocking Reagent (BR), Immunohistochemistry (IHC), Surface Plasmon Resonance (SPR)
- Purpose
- Anti-PD-1 [5C4.B8 (Nivolumab)], Rabbit IgG, kappa
- Specificity
- Nivolumab binds to the extracellular portion of human PD-1 (2.6 nM - Scatchard analysis and SPR) - the antibody also binds to cynomolgus PD-1 with a similar affinity (3.9 nM - SPR). The antibody does not bind to other immunoglobulin superfamily proteins such as CD28, CTLA-4, ICOS and BTLA. The epitope of Nivolumab for both human and cynomolgus PD-1 includes the sequences SFVLNWYR-MSPSNQTDKLAAFPEDR (aa 29-53) and SGTYLCGAISLAPKAQIKE (aa 85-103), as shown by mass spectrometry of protease-treated fragments of PD-1 - these residues are thought to additionally be important for liand binding to PD-1. PD-1 is an inhibitory receptor expressed on the surface of T cells. It is able to bind to its ligands PDL-1 and PDL-2 which results in an inhibitory signal leading to decreased T cell proliferation, cytokine protuction and cytotoxic activtiy. PDL-1 is often expressed in human tumors such as melanoma, lung and kidney where it is able to overactivate PD-1 and plays a role in the evasion of cancer cells from the immune system.
- Cross-Reactivity
- Cynomolgus
- Characteristics
-
Original Species of Ab: Human
Original Format of Ab: IgG4
- Purification
- Protein A affinity purified
- Immunogen
- mAb PD1.5 was prepared by immunizing IgH and IgK knock-out transgenic mice possessing a human immunoglobulin (heavy chain) minilocus with recombinant human PD-1-Fc protein consisting of the extracellular domain of PD-1 (amino acids 1-167) and the Fc portion of human IgG1, and Chinese hamster ovary (CHO) cells expressing human PD-1. Nivolumab was generated by grafting the variable regions of PD1.5 onto human kappa and IgG4 constant regions containing an S228P mutation (prevents Fab arm exchange with endogenous IgG4 antibodies).
- Clone
- 5C4-B8
- Isotype
- IgG kappa
-
-
- Application Notes
- Nivolumab has been shown to bind to PD-1-expressing CHO cells (EC50 ~1.66nM). Nivolumab binds CD4+ T cells (EC50 ~0.64 nM) and stains only memory and effector, and not naiive CD4+ or CD8+ T cells from human peripheral blood by FC. The antibody is able to block the interaction between PD-1 and its ligands PDL-1 and PDL-2 (IC50 ~2.52 nM and ~2.59 nM, respectively - determined by SPR) - these IC50 values are also similar to that measured by FACS to evaluate ligand binding to PD-1 expressed on CHO cells. In an allogenic T-cell/DC MLR, Nivolumab-mediated inhibition of PD-1 results in enhancement of IFNγ release, and also enhances IL-2 secretion (97-139 % over an isotype control) in response to the superantigen SEB using human peripheral blood mononuclear cells. The same is also observed in a CMV-restimulation assay. Nivolumab at very low concentrations (~1.5 ng/mL) is able to enhance T-cell reactivity in the presence of a T-cell receptor stimulus - nivolumab has no stimulatory effect in the absence of antigen or T-cell receptor stimulus. In the therapeutically used human IgG4 (S228P) format, this antibody is unable to mediate ADCC (antibody-dependent cell-mediated cytotoxicity) or CDC (complement-dependent cytotoxicity).
- Comment
-
This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- PBS with 0.02 % Proclin 300.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- Target
- PDCD1 (Nivolumab Biosimilar)
- Abstract
- PDCD1 (Nivolumab Biosimilar) Products
- Target Type
- Biosimilar
- Background
- CD279, programmed death-1, programmed death 1 , PD1, PD 1, Programmed cell death protein 1, hPD-1, hPD1, hPD 1, BMS-936558, MDX-1106,ONO-4538
- UniProt
- Q15116
-
You are here:
